Veradermics Inc (MANE) Stock Analysis
Verdict: HOLD
Positive Phase 2 hair loss data validates the pipeline, but a $4.4B valuation for a pre-revenue firm makes entry timing at support critical.
Investment score: 64/100
Analysis as of
Is Veradermics Inc stock worth reviewing? AI model thesis
MANE is a high-conviction biotech play with validated Phase 2 data, strong institutional backing (Suvretta Capital), and a clear path to a massive hair-loss market. The recent 15% pullback is viewed as a strategic entry opportunity.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 95/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Veradermics Inc opportunities and risks
What speaks for MANE
- Clinical Validation of VDPHL01
What speaks against MANE
- Excessive Valuation Expectations
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MANE | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.0% |
| BLTE | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| LGND | 37.8x | 21.6x | 28.2x | 98.6% | 55.9% | 2.1% |
| DFTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.0% |
| AMRX | 47.6x | 1.9x | 13.2x | 38.7% | 4.0% | 3.6% |
| INDV | 20.2x | 3.9x | 15.3x | 83.1% | 19.4% | -3.6% |
| Peer median | 20.2x | 1.9x | 13.2x | 38.7% | 4.0% | -0.0% |
Frequently asked questions about Veradermics Inc (MANE)
Is MANE stock a good investment?
The cached TradeMates AI model rates Veradermics Inc as HOLD with an investment score of 64/100. MANE is a high-conviction biotech play with validated Phase 2 data, strong institutional backing (Suvretta Capital), and a clear path to a massive hair-loss market. The recent 15% pullback is viewed as a strategic entry opportunity. This is algorithmic model output, not personal investment advice.
Is MANE stock a buy?
The TradeMates model verdict for MANE is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.